Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2027

Conditions
Foot Ulcers, Diabetic
Interventions
DRUG

Topical application of Plasma Rich in Growth Factors (PRGF)

Topical application of PRGF will be maintained each time the patient undergoes the conventional treatment. The frequency of conventional treatment will be determined by the health specialist according to the evolution of the ulcer. The treatment will be maintained until complete wound closure or until the end of the follow-up period (6 months).

PROCEDURE

Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).

"Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic). The TIME dynamic wound closure strategy will be followed, which summarizes the four key points to stimulate the natural healing process: control of non-viable tissue, control of inflammation and infection, control of exudate and stimulation of the edges. After healing, chlorhexidine spray will be applied topically to these patients. The frequency of conventional treatment will be determined by the health specialist according to the evolution of the ulcer. Treatment will be maintained until complete wound closure or until the end of the follow-up period (6 months)."

Trial Locations (1)

48013

RECRUITING

Hospital Universitario de Basurto., Bilbao

Sponsors
All Listed Sponsors
collaborator

Hospital de Basurto

OTHER

lead

Biotechnology Institute IMASD

INDUSTRY